HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G CEO bonus

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble raised the annual bonus for President and CEO A.G. Lafley by 33.3% to $3 mil. in fiscal 2003 (ended June 30), company reports in Securities and Exchange Commission 1filing Aug. 28. Bonus is based on Lafley's individual performance and the annual bonus awards paid to CEOs of comparable companies, filing notes. Exec has led a successful restructuring initiative since becoming head of the company in 2000 (2"The Rose Sheet" June 12, 2000, p. 11). Lafley's salary for 2003 was $1.6 mil., compared with $1.4 mil. in the prior year, according to the filing...

You may also be interested in...



P&G Beauty Head Lafley Named CEO, Pepper Reinstated As Chairman

Procter & Gamble CEO-elect A.G. Lafley will use his past experience in revitalizing P&G's hair care business to recharge the consolidated company and forge a more carefully paced strategic direction. Lafley succeeds Durk Jager, who will retire July 1.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel